Approaches to develop therapeutics to treat frontotemporal dementia - PubMed (original) (raw)

Review

Approaches to develop therapeutics to treat frontotemporal dementia

Lisa P Elia et al. Neuropharmacology. 2020 Apr.

Abstract

Frontotemporal degeneration (FTD) is a complex disease presenting as a spectrum of clinical disorders with progressive degeneration of frontal and temporal brain cortices and extensive neuroinflammation that result in personality and behavior changes, and eventually, death. There are currently no effective therapies for FTD. While 60-70% of FTD patients are sporadic cases, the other 30-40% are heritable (familial) cases linked to mutations in several known genes. We focus here on FTD caused by mutations in the GRN gene, which encodes a secreted protein, progranulin (PGRN), that has diverse roles in regulating cell survival, immune responses, and autophagy and lysosome function in the brain. FTD-linked mutations in GRN reduce brain PGRN levels that lead to autophagy and lysosome dysfunction, TDP43 accumulation, excessive microglial activation, astrogliosis, and neuron death through still poorly understood mechanisms. PGRN insufficiency has also been linked to Alzheimer's disease (AD), and so the development of therapeutics for GRN-linked FTD that restore PGRN levels and function may have broader application for other neurodegenerative diseases. This review focuses on a strategy to increase PGRN to functional, healthy levels in the brain by identifying novel genetic and chemical modulators of neuronal PGRN levels. This article is part of the special issue entitled 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.

Keywords: AD; FTD; Lysosome; Neurodegenerative; Progranulin; Therapeutics.

Copyright © 2020 Elsevier Ltd. All rights reserved.

PubMed Disclaimer

References

    1. Rabinovici GD & Miller BL Frontotemporal lobar degeneration: epidemiology, pathophysiology, diagnosis and management. CNS Drugs 24, 375–398 (2010). -PMC -PubMed
    1. Rademakers R, Neumann M & Mackenzie IR Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol 8, 423–434 (2012). -PMC -PubMed
    1. Riedl L, Mackenzie IR, Forstl H, Kurz A & Diehl-Schmid J. Frontotemporal lobar degeneration: current perspectives. Neuropsychiatr Dis Treat 10, 297–310 (2014). -PMC -PubMed
    1. Greaves CV & Rohrer JD An update on genetic frontotemporal dementia. J Neurol 266, 2075–2086 (2019). -PMC -PubMed
    1. Curtis AF et al. Sex differences in the prevalence of genetic mutations in FTD and ALS: A meta-analysis. Neurology 89, 1633–1642 (2017). -PMC -PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources